947 related articles for article (PubMed ID: 17721103)
1. Risk of cancers during interrupted antiretroviral therapy in the SMART study.
Silverberg MJ; Neuhaus J; Bower M; Gey D; Hatzakis A; Henry K; Hidalgo J; Lourtau L; Neaton JD; Tambussi G; Abrams DI
AIDS; 2007 Sep; 21(14):1957-63. PubMed ID: 17721103
[TBL] [Abstract][Full Text] [Related]
2. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death.
Holkmann Olsen C; Mocroft A; Kirk O; Vella S; Blaxhult A; Clumeck N; Fisher M; Katlama C; Phillips AN; Lundgren JD;
HIV Med; 2007 Mar; 8(2):96-104. PubMed ID: 17352766
[TBL] [Abstract][Full Text] [Related]
3. AIDS-defining and non-AIDS-defining malignancies: cancer occurrence in the antiretroviral therapy era.
Silverberg MJ; Abrams DI
Curr Opin Oncol; 2007 Sep; 19(5):446-51. PubMed ID: 17762569
[TBL] [Abstract][Full Text] [Related]
4. The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART)in a London clinic.
Ives NJ; Gazzard BG; Easterbrook PJ
J Infect; 2001 Feb; 42(2):134-9. PubMed ID: 11531320
[TBL] [Abstract][Full Text] [Related]
5. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy.
Clifford GM; Polesel J; Rickenbach M; Dal Maso L; Keiser O; Kofler A; Rapiti E; Levi F; Jundt G; Fisch T; Bordoni A; De Weck D; Franceschi S;
J Natl Cancer Inst; 2005 Mar; 97(6):425-32. PubMed ID: 15770006
[TBL] [Abstract][Full Text] [Related]
6. CD4+ guided antiretroviral treatment interruption in HIV infection: a meta-analysis.
Seminari E; De Silvestri A; Boschi A; Tinelli C
AIDS Rev; 2008; 10(4):236-44. PubMed ID: 19092979
[TBL] [Abstract][Full Text] [Related]
7. Ten years later: a single hospital experience with malignancy in HIV/AIDS.
Reed M; Cosgrove JM; Cindrich R; Parithivel VS; Gad Y; Bangalore M; Uzor R; Kalim J; Segura R; Albu E
J Surg Oncol; 2010 Sep; 102(3):282-6. PubMed ID: 20740588
[TBL] [Abstract][Full Text] [Related]
8. Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals.
Burgi A; Brodine S; Wegner S; Milazzo M; Wallace MR; Spooner K; Blazes DL; Agan BK; Armstrong A; Fraser S; Crum NF
Cancer; 2005 Oct; 104(7):1505-11. PubMed ID: 16104038
[TBL] [Abstract][Full Text] [Related]
9. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
Panel de expertos de Gesida y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
[TBL] [Abstract][Full Text] [Related]
10. The growing problem of non-AIDS-defining malignancies in HIV.
Pantanowitz L; Schlecht HP; Dezube BJ
Curr Opin Oncol; 2006 Sep; 18(5):469-78. PubMed ID: 16894295
[TBL] [Abstract][Full Text] [Related]
11. Trends in AIDS-defining and non-AIDS-defining malignancies among HIV-infected patients: 1989-2002.
Bedimo R; Chen RY; Accortt NA; Raper JL; Linn C; Allison JJ; Dubay J; Saag MS; Hoesley CJ
Clin Infect Dis; 2004 Nov; 39(9):1380-4. PubMed ID: 15494916
[TBL] [Abstract][Full Text] [Related]
12. Delayed diagnosis of HIV infection and late initiation of antiretroviral therapy in the Swiss HIV Cohort Study.
Wolbers M; Bucher HC; Furrer H; Rickenbach M; Cavassini M; Weber R; Schmid P; Bernasconi E; Hirschel B; Battegay M;
HIV Med; 2008 Jul; 9(6):397-405. PubMed ID: 18410354
[TBL] [Abstract][Full Text] [Related]
13. Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy.
Bonnet F; Lewden C; May T; Heripret L; Jougla E; Bevilacqua S; Costagliola D; Salmon D; Chêne G; Morlat P
Cancer; 2004 Jul; 101(2):317-24. PubMed ID: 15241829
[TBL] [Abstract][Full Text] [Related]
14. [AIDS-associated Kaposi's sarcoma: 22 cases].
Dhrif AS; Kilani B; Ammari L; Kanoun F; Tiouri H; Ben Chaaben T
Tunis Med; 2007 Jun; 85(6):494-9. PubMed ID: 17644904
[TBL] [Abstract][Full Text] [Related]
15. Less cancer--or more--with HAART? Or, reflections on a late opus.
Mascolini M
J Int Assoc Physicians AIDS Care; 1998 Jun; 4(6):12-22. PubMed ID: 11365531
[TBL] [Abstract][Full Text] [Related]
16. AIDS-associated cancers: an emerging challenge.
Phatak UA; Joshi R; Badakh DK; Gosavi VS; Phatak JU; Jagdale RV
J Assoc Physicians India; 2010 Mar; 58():159-62. PubMed ID: 20848813
[TBL] [Abstract][Full Text] [Related]
17. AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy.
Cheung MC; Pantanowitz L; Dezube BJ
Oncologist; 2005; 10(6):412-26. PubMed ID: 15967835
[TBL] [Abstract][Full Text] [Related]
18. HIV infection and cancer in the era of highly active antiretroviral therapy (Review).
Barbaro G; Barbarini G
Oncol Rep; 2007 May; 17(5):1121-6. PubMed ID: 17390054
[TBL] [Abstract][Full Text] [Related]
19. Evolving epidemiology of malignancies in HIV.
Bonnet F; Chêne G
Curr Opin Oncol; 2008 Sep; 20(5):534-40. PubMed ID: 19106656
[TBL] [Abstract][Full Text] [Related]
20. Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study.
Simcock M; Blasko M; Karrer U; Bertisch B; Pless M; Blumer L; Vora S; Robinson JO; Bernasconi E; Terziroli B; Moirandat-Rytz S; Furrer H; Hirschel B; Vernazza P; Sendi P; Rickenbach M; Bucher HC; Battegay M; Koller MT;
Antivir Ther; 2007; 12(6):931-9. PubMed ID: 17926647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
